ATE406901T1 - Verwendung von mit kohlenstoff-2 modifizierten vitamin-d-analoga zur einleitung der neuen knochenbildung - Google Patents

Verwendung von mit kohlenstoff-2 modifizierten vitamin-d-analoga zur einleitung der neuen knochenbildung

Info

Publication number
ATE406901T1
ATE406901T1 AT03716465T AT03716465T ATE406901T1 AT E406901 T1 ATE406901 T1 AT E406901T1 AT 03716465 T AT03716465 T AT 03716465T AT 03716465 T AT03716465 T AT 03716465T AT E406901 T1 ATE406901 T1 AT E406901T1
Authority
AT
Austria
Prior art keywords
carbon
new bone
bone
analogs
growth
Prior art date
Application number
AT03716465T
Other languages
English (en)
Inventor
Hector Deluca
J Pike
Nirupama Shevde
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28673538&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE406901(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Application granted granted Critical
Publication of ATE406901T1 publication Critical patent/ATE406901T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Prostheses (AREA)
AT03716465T 2002-03-25 2003-03-12 Verwendung von mit kohlenstoff-2 modifizierten vitamin-d-analoga zur einleitung der neuen knochenbildung ATE406901T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/105,826 US20030195175A1 (en) 2002-03-25 2002-03-25 Use of carbon-2-modified-vitamin D analogs to induce the formation of new bone

Publications (1)

Publication Number Publication Date
ATE406901T1 true ATE406901T1 (de) 2008-09-15

Family

ID=28673538

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03716465T ATE406901T1 (de) 2002-03-25 2003-03-12 Verwendung von mit kohlenstoff-2 modifizierten vitamin-d-analoga zur einleitung der neuen knochenbildung

Country Status (20)

Country Link
US (3) US20030195175A1 (de)
EP (1) EP1494680B1 (de)
JP (1) JP2005527558A (de)
KR (1) KR100983953B1 (de)
CN (1) CN100531739C (de)
AT (1) ATE406901T1 (de)
AU (1) AU2003220169B2 (de)
BR (1) BR0308701A (de)
CA (1) CA2480125C (de)
DE (1) DE60323351D1 (de)
DK (1) DK1494680T3 (de)
ES (1) ES2312764T3 (de)
HK (1) HK1079996B (de)
IL (1) IL164275A0 (de)
MX (1) MXPA04009288A (de)
NZ (1) NZ535843A (de)
PL (1) PL372346A1 (de)
PT (1) PT1494680E (de)
WO (1) WO2003082300A1 (de)
ZA (1) ZA200408153B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005027928A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. 2-alkylidene-19-nor-vit amin d derivatives for the treatment of hypocalcemic tetany or hyproparathyroidism
AU2004273658A1 (en) * 2003-09-19 2005-03-31 Wisconsin Alumni Research Foundation (Warf) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an estrogen agonist/antagonist
NZ545393A (en) * 2003-09-19 2009-10-30 Wisconsin Alumni Res Found 2-Alkylidene-19-nor-vitamin D derivatives for the treatment of osteopenia or male osteoporosis
NZ545632A (en) * 2003-09-19 2009-09-25 Wisconsin Alumni Res Found 2-Alkylidene-19-nor-vitamin D derivatives for the treatment of frailty, muscle damage or sarcopenia
WO2005027919A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture
US7214671B2 (en) * 2004-02-19 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases
US7592176B2 (en) 2004-05-07 2009-09-22 Wisconsin Alumni Research Foundation Method of forming mesenchymal stem cells from embryonic stem cells
WO2006061683A1 (en) * 2004-12-09 2006-06-15 Pfizer Products Inc. 2-alkylidene-19-nor-vitamin d derivatives for the treatment of osteogenesis imperfecta
US7528122B2 (en) 2006-02-02 2009-05-05 Wisconsin Alumni Research Foundation Vitamin D analog—NEL, methods and uses thereof
US7803789B2 (en) * 2006-02-02 2010-09-28 Wisconsin Alumni Research Foundation Vitamin D analog—RAK, methods and uses thereof
EP2419403B1 (de) * 2009-04-17 2016-09-07 Vidasym, Inc. Agonisten des vitamin-d-rezeptors und anwendungen davon
JP6971966B2 (ja) * 2015-08-05 2021-11-24 ウイスコンシン アラムニ リサーチ ファンデーション カルシトリオールの2−メチレン類似体および関連化合物の合成および生物活性
CN111588506B (zh) * 2020-01-02 2022-01-25 南京医科大学 一种含维生素c的钛种植体存储液的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US584928A (en) * 1897-06-22 Schlag
US4666634A (en) * 1984-12-05 1987-05-19 Chugai Seiyaku Kabushiki Kaisha vitamin D3 derivatives having a substituent at 2-position
IL74617A (en) * 1985-03-15 1988-11-15 Yeda Res & Dev Compositions comprising a vitamin d derivative and method for the local treatment of bone fractures in animals
CA1333616C (en) * 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
US5246925A (en) * 1989-03-09 1993-09-21 Wisconsin Alumni Research Foundation 19-nor-vitamin D compounds for use in treating hyperparathyroidism
US5556645A (en) * 1990-01-12 1996-09-17 Bockman; Richard Methods of enhancing wound healing and tissue repair
US5086191A (en) * 1991-05-28 1992-02-04 Wisconsin Alumni Research Foundation Intermediates for the synthesis of 19-nor vitamin D compounds
JP2898882B2 (ja) * 1993-04-05 1999-06-02 ウイスコンシン アラムナイ リサーチ フオンデーシヨン 2−位に置換基を有する19−ノル−ビタミンd3 化合物
US5565589A (en) * 1993-11-03 1996-10-15 Wisconsin Alumni Research Foundation 17-formyl-5,6-trans-vitamin D compounds
US5428029A (en) * 1993-11-24 1995-06-27 Hoffmann-La Roche Inc. Vitamin D3 fluorinated analogs
EP1021401A1 (de) * 1995-09-21 2000-07-26 Wisconsin Alumni Research Foundation Calcitriol derivate und ihre verwendungen
US5976142A (en) * 1996-10-16 1999-11-02 Chin; Martin Apparatus and method for distraction osteogenesis of small alveolar bone
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
US5843928A (en) * 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US6306844B1 (en) * 1997-03-17 2001-10-23 Wisconsin Alumni Research Foundation Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength
US5945410A (en) * 1997-03-17 1999-08-31 Wisconsin Alumni Research Foundation 2-alkyl-19-nor-vitamin D compounds
ES2320603T3 (es) * 1997-07-30 2009-05-25 Emory University Sistemas de expresion, vectores, adn, proteinas de mineralizacion osea novedosos.
BR0112454A (pt) * 2000-07-14 2003-07-29 Wisconsin Alumni Res Found Métodos de tratamento de doença metabólica do osso, psorìase, leucemia, câncer do cólon, do seio ou da próstata e de aumento da força de um osso e uso de composto

Also Published As

Publication number Publication date
KR100983953B1 (ko) 2010-09-27
MXPA04009288A (es) 2005-06-08
US20110112056A1 (en) 2011-05-12
JP2005527558A (ja) 2005-09-15
EP1494680B1 (de) 2008-09-03
CN100531739C (zh) 2009-08-26
DE60323351D1 (de) 2008-10-16
AU2003220169B2 (en) 2008-09-11
PL372346A1 (en) 2005-07-11
NZ535843A (en) 2006-03-31
PT1494680E (pt) 2008-10-21
BR0308701A (pt) 2005-01-18
KR20040095346A (ko) 2004-11-12
IL164275A0 (en) 2005-12-18
AU2003220169A1 (en) 2003-10-13
US20050203071A1 (en) 2005-09-15
ES2312764T3 (es) 2009-03-01
CN1655797A (zh) 2005-08-17
ZA200408153B (en) 2006-03-29
WO2003082300A1 (en) 2003-10-09
CA2480125A1 (en) 2003-10-09
DK1494680T3 (da) 2008-11-17
HK1079996A1 (zh) 2006-04-21
US20030195175A1 (en) 2003-10-16
EP1494680A1 (de) 2005-01-12
HK1079996B (zh) 2010-04-01
CA2480125C (en) 2009-12-29

Similar Documents

Publication Publication Date Title
Hing et al. Effect of silicon level on rate, quality and progression of bone healing within silicate-substituted porous hydroxyapatite scaffolds
DE60323351D1 (de) Verwendung von mit kohlenstoff-2 modifizierten vitamin-d-analoga zur einleitung der neuen knochenbildung
NO20040331L (no) Legemidler for sykdommer med benmassetap som har Eragonist som den aktive bestanddel
ATE414089T1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
EA201001286A1 (ru) Комбинированное применение 25-гидроксивитамина d3 и витамина d3 для повышения плотности минерального вещества костей и для лечения остеопороза
IL153908A0 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING 2alpha-METHYL-19-NOR-20(S)-1alpha, 25-DIHYDROXYVITAMIN D3
MXPA05007181A (es) Cristales de la hormona de crecimiento humano y metodos para prepararlos.
NO20051008L (no) Nye imidazolforbindelser som transformerende vekst faktor (TGF) inhibitorer
ATE535239T1 (de) Formulierungen enthaltend amiodaron und sulfoalkylethercyclodextrin
ATE365045T1 (de) Vermehrung des weich- sowie des knochengewebes anhand von aus muskeln stammenden vorläuferzellen,sowie damit verbundene zusammensetzungen und behandlungsformen
NO331024B1 (no) Anvendelse av risendroninsyre for forebygging eller behandling av osteoporose
MXPA04001334A (es) Materiales y metodos para promover la reparacion de tejido nervioso.
WO2004026239A3 (en) Use of beta glucans for the treatment of osteoporosis and other diseases of bone resorption
WO2015009991A8 (en) Methods, systems, and compositions for promoting bone growth
Chandran et al. Osseointegration of osteoporotic bone implants: Role of stem cells, Silica and Strontium-A concise review
MXPA03000406A (es) Uso de 2-metilen-19-nor-20(s)-1 alfa,25-dihidroxivitamina d3 para incrementar la resistencia de los huesos.
EP1642600A4 (de) Medizinisches knochenprothesematerial und verfahren zu seiner herstellung
CU23352A1 (es) Biomateriales compuestos para implantes óseos
ATE370941T1 (de) Modulatoren des vitamin-d-rezeptors
ATE198418T1 (de) Pharmazeutische zusammensetzung zur förderung der gewebeheilung und -regenerierung und darreichungssatz
WO2004019873A3 (en) Methods of promoting osteogenesis
DE02748548T1 (de) Calcium-l-threonat zur prävention oder behandlung von knochenfrakturen
ATE413863T1 (de) Sprudelnde pharmazeutische zusammensetzungen mit vitamin d, calcium und phospat und ihre therapeutische verwendung
Hardt et al. Osteosynthesis in Craniofacial Fractures
WO2003059277A3 (en) Methods and compositions for stimulating bone growth using inhibitors of microtubule assembly

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1494680

Country of ref document: EP